Literature DB >> 11416681

Choosing initial antihypertensive drug therapy for the uncomplicated hypertensive patient.

M A Moore1.   

Abstract

Choosing the initial antihypertensive drug for the uncomplicated hypertensive patient is an important and frequent event for the primary care physician. Patients' first experience with antihypertensive drug therapy will likely affect their long-term perception of hypertension treatment. The choice should be made on the basis of sound scientific data and from the patient's perspective and needs. The drug should be taken once a day, should have proven efficacy in hypertension control and cardiovascular morbidity and mortality reduction, and should have as few side effects as possible. Low-dose thiazide diuretics meet this description, although the need to monitor electrolytes may make them less than ideal. The angiotensin II receptor antagonist class, with side-effects similar to those of placebo in controlled trials, is the most attractive from the patient's perspective, although outcome trial data do not yet exist proving that hypertension treatment with angiotensin II receptor antagonists reduces cardiovascular events. The angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists, with their low side-effect profiles and unique effects on vascular remodeling, are attractive second choices to combine with a diuretic if needed, although low-dose diuretic/Beta blocker combinations have also been shown to lower blood pressure with minimal side effects. At present, ensuring adequate long-term hypertension control is the most important aspect of hypertensive care, and which antihypertensive drug(s) the physician chooses can greatly affect the hypertensive patient's ability to achieve and to maintain long-term blood pressure control. (c)2001 by Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11416681      PMCID: PMC8101857          DOI: 10.1111/j.1524-6175.2001.990830.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  49 in total

Review 1.  Beta-adrenergic blockade for survivors of acute myocardial infarction.

Authors:  W H Frishman; C D Furberg; W T Friedewald
Journal:  N Engl J Med       Date:  1984-03-29       Impact factor: 91.245

Review 2.  Anti-renin system therapy. A new horizon for understanding and treating hypertension.

Authors:  J H Laragh
Journal:  Am Heart J       Date:  1981-03       Impact factor: 4.749

3.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

4.  Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.

Authors:  J V Gainer; J D Morrow; A Loveland; D J King; N J Brown
Journal:  N Engl J Med       Date:  1998-10-29       Impact factor: 91.245

5.  Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

Authors:  B Dahlöf; R B Devereux; S Julius; S E Kjeldsen; G Beevers; U de Faire; F Fyhrquist; T Hedner; H Ibsen; K Kristianson; O Lederballe-Pedersen; L H Lindholm; M S Nieminen; P Omvik; S Oparil; H Wedel
Journal:  Hypertension       Date:  1998-12       Impact factor: 10.190

6.  Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.

Authors:  J H MacKay; K E Arcuri; A I Goldberg; S M Snapinn; C S Sweet
Journal:  Arch Intern Med       Date:  1996-02-12

7.  Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.

Authors:  B A Soffer; J T Wright; J H Pratt; B Wiens; A I Goldberg; C S Sweet
Journal:  Hypertension       Date:  1995-07       Impact factor: 10.190

Review 8.  The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview.

Authors:  R S Vasan; D Levy
Journal:  Arch Intern Med       Date:  1996-09-09

9.  Minoxidil, nadolol, and a diuretic. Once-a-day therapy for resistant hypertension.

Authors:  S Spitalewitz; J G Porush; I W Reiser
Journal:  Arch Intern Med       Date:  1986-05

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  1 in total

Review 1.  Safety and tolerability of eprosartan in combination with hydrochlorothiazide.

Authors:  Michael Böhm; Alisia Sachse
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.